Intuniv (Guanfacine)

Guanfacine selectively activates alpha-2A adrenergic receptors in the brainstem, decreasing norepinephrine release. This reduces sympathetic outflow, leading to lower blood pressure and enhanced prefrontal cortical function, which supports attention and impulse control.

The appropriate dose of Intuniv is determined by a qualified prescriber based on the patient’s age, condition, and response. Dosage adjustments are made under medical supervision to achieve the desired therapeutic effect.

Safety data for guanfacine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Intuniv (guanfacine) is a non‑stimulant option that targets alpha-2A receptors, whereas many other ADHD drugs are stimulants that increase dopamine and norepinephrine levels. Intuniv may be preferred when stimulant side effects are problematic or when a patient requires a different mechanism of action.

Intuniv tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children.

Intuniv is taken orally as an extended‑release tablet, usually once daily in the morning or as directed by a healthcare provider. The tablet should be swallowed whole with water and not crushed or chewed.

Serious risks include severe hypotension, bradycardia, syncope, heart block, liver function abnormalities, and rare allergic reactions such as rash or angioedema. Patients should be monitored regularly for these events, especially during dose changes.

Intuniv is contraindicated in patients with known hypersensitivity to guanfacine or any tablet components, and it should be used with caution in individuals with severe cardiac conduction disorders, uncontrolled hypertension, or significant liver impairment.